Moderna Adds Herpes Vaccine Candidate to Pipeline

Moderna is entering the global race for a Herpes vaccine. Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts that focuses on RNA therapeutics, primarily mRNA vaccines.  They are best known for recent success with their mRNA-based COVID-19 vaccine.

From Moderna website: Moderna’s herpes simplex virus (HSV) vaccine candidate (mRNA-1608) is a vaccine candidate against HSV-2 disease. Moderna expects that an HSV-2 vaccine could provide cross-protection against HSV-1. With mRNA-1608, the Company aims to induce strong antibody response with neutralizing and effector functionality combined with cell-mediated immunity. There is no vaccine approved against HSV.

More details on the Moderna website here.


Get in Touch


Have a news tip? Are you working on clinical research for HSV treatments and want to share updates with the public? Let us know!

Never miss a thing. Sign up for emails.

Processing…
Success! You're on the list.

One thought on “Moderna Adds Herpes Vaccine Candidate to Pipeline

Leave a Reply to Diondra Sams Cancel reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: